The Canadian Hemophilia Society (CHS) is proud to put out its call for applications for its research programs for the 2025-2026 grant period. The deadline to submit applications for all the programs is November 29, 2024. The eligibility criteria and conditions for all our research programs have been revised and updated. Of note, applications must now be done on-line at the links provided on our website under each research program heading and, eligibility has been expanded as follows:

Dream of a Cure: the program is no longer limited to hemophilia A & B-related projects so that projects focusing on von Willebrand disease, rare factor deficiencies, platelet function disorders (and platelet pathophysiology) and other congenital and acquired bleeding disorders can be supported;

Dream of a Cure Studentships in Inherited Bleeding Disorders Research: similarly to our basic scientific research program, the studentships are no longer limited to hemophilia-related projects but include all inherited bleeding disorders. Furthermore, science students in any year of an undergraduate program can apply in addition to medical students in any year of training;

CHS/Pfizer Care Until Cure Research Program: the areas of interest to which investigators are encouraged to submit proposals has been expanded to include assessing joint function, FIX/FVIII assay discrepancy across gene therapy recipients, methodology for monitoring patients treated with anti-TFPI therapies; all projects included but not limited to the list will be considered;

CHS/Novo Nordisk Psychosocial Research Programme: applications from Social Workers, Nurses, or Physiotherapists with professional experience in a hemophilia treatment centre (or other comparable settings in which care has been provided to people with hemophilia and other inherited bleeding disorders) or persons interested in the field of inherited bleeding disorders will be considered. Students in a PhD program in one of the allied health disciplines may also apply. Professionals who have appointments in universities and who can dedicate time to research are encouraged to apply. Professional experience in a hemophilia treatment centre is desirable but not required.

CHS/Bayer ADVANCE Canada Research Program:  applicant must be a physician or Ph.D. or professionals from the allied health disciplines (ie. Nursing, Physiotherapy & Social Work) with professional experience in a hemophilia treatment centre (HTC) or other comparable settings in which care has been provided to people with hemophilia and other inherited bleeding disorders. Professionals who have appointments in universities and who can dedicate time to research are encouraged to apply. The proposed research must have relevance to current practice in bleeding disorders care and may incorporate a broad spectrum of quantitative and qualitative research methods addressing professional practice with individuals, families, groups and communities, organizational issues, public health, and education. The research studies should aim to provide better data and tools to help the treaters assist patients in successful ageing.

DREAM OF A CURE

Through funds provided by the Hemophilia Research Million Dollar Club and the CHS, the CHS provides basic scientific research grants and studentships aimed at developing treatments for hemophilia A and B, von Willebrand disease, rare factor deficiencies, platelet function disorders and ultimately, finding a cure.

Dream of a Cure, the CHS Research Program and the 2025 Dream of a Cure Summer Studentships in Inherited Bleeding Disorders Research on-line application forms links as well as the general criteria and conditions are available by accessing the CHS Web site at https://www.hemophilia.ca/chs-dream-of-a-cure-research-program/. For Dream of a Cure, individual grants will be awarded to researchers for one to two years for amounts up to $75,000 per year while support will be offered to interested Canadian medical or science students for up to 4 months for a maximum stipend of $6,000 per student. 

______________________________

CHS / PFIZER CARE UNTIL CURE RESEARCH PROGRAM

You will find at https://www.hemophilia.ca/the-chspfizer-care-until-cure-research-program/ the information and the on-line application link for the CHS/Pfizer Care until Cure Research Program offered by the CHS in collaboration with Pfizer Canada. This program allows Canadian investigators to conduct research on medical and psychosocial aspects of bleeding disorders. Grants for one to two years with a maximum of $75,000 per year will be awarded for clinical research, including outcome evaluation, in fields relevant to improving the health and the quality of life for persons with Hemophilia, persons with von Willebrand disease or other inherited bleeding disorders, persons with related conditions such as HIV or hepatitis C infection, and carriers of an inherited bleeding disorder.

 
______________________________

CHS/Novo Nordisk canada Psychosocial Research Programme

The CHS/Novo Nordisk Canada Psychosocial Research Program was created to engage hemophilia program professionals/graduate students from the allied health disciplines (ie. Nursing, Physiotherapy & Social Work) in research activities addressed to understanding the psychosocial impact of hemophilia and other inherited bleeding disorders and to improve the quality of life of persons and families whose lives are affected by these disorders.

The primary intent of this program is to offer one or two $20,000 research grants, to a maximum of $40,000 for one year.Depending upon the number and quality of applications, funding for different amounts is possible, as is the offering of more than one research grant, within however, the allotted total budget stated above.

The major portion of the grant would be to cover the research time for the successful candidate(s), including the time for research assistants. A small amount can be devoted to project expenses.

Multidisciplinary Collaboration:
Collaboration with multidisciplinary care providers and/or between two or more hemophilia centres is accepted and encouraged. Collaboration efforts may include, for example, social work, physical therapy and genetics. It thus may be possible for a hemophilia centre team to jointly submit a cooperative research project. Additionally, inter-regional applications will be considered.
 
Grants will be offered for a one-year period to begin in April 2025.

More detailed information and the on-line application link are available by accessing the CHS Web site at https://www.hemophilia.ca/the-chsnovo-nordisk-psychosocial-research-program/

______________________________

The Canadian Hemophilia Society – Bayer ADVANCE Canada Research Program

The Canadian Hemophilia Society – Bayer ADVANCE Canada Research Program was created to engage Canadian hemophilia treaters in activities to identify and research key issues in the ageing hemophilia population.

The research program will support studies that aim to:

•             Identify and provide insight into key issues associated with the ageing hemophilia population

•             Identify how management of age-related co-morbidities should be adapted to those with hemophilia

•             Create and deliver evidence-based information to health care practitioners (HCPs), the public and policy makers that will lead to improved care and QoL for older Canadians living with hemophilia

The primary intent of this program is to offer one or two $22,500 research grants, to a maximum of $45,000 for one year. Depending upon the number and quality of applications, funding for different amounts is possible, as is the offering of more than one research grant, within however, the allotted total budget stated above.

Additional information, the on-line application link, the eligibility criteria and conditions for the research program can be found on our website at this link:

https://www.hemophilia.ca/research-chs-bayer-advance-canada-research-program/

The specific objectives of the CCNA Research Teams FO are to equitably and inclusively:

• Support research in age-related neurogenerative diseases related to the themes of primary prevention, secondary prevention and treatment, and quality of life;
• Support the continuous improvement and optimal use of CCNA research platforms and central research support for research in neurodegeneration in aging;
• Catalyze and build training and mentoring capacity to foster career development of the next generation of researchers in the field, inclusive of the diversity of people in Canada, and Australia, as applicable, by leveraging training and other opportunities offered by the CCNA Operations Centre;
• Enhance capacity for knowledge mobilization practices throughout the research process, in both official languages, to increase the dissemination and uptake of neurodegenerative disease research results to relevant parties and partners in research;
• Facilitate interdisciplinary, interinstitutional, interprovincial, and international (if applicable) collaborations, and create linkages within and across teams, themes, and the CCNA Operations Centre, and between a diversity of researchers and knowledge users in age-related neurodegenerative diseases; and
• Advance research on neurodegenerative diseases and improve more equitable health outcomes for diverse groups of people in Canada, and Australia, as applicable.

See "Additional Information" for more details on the overall objectives of the CCNA in Phase III.

Eureka has launched a Globalstars call for proposals for joint research and development (R&D) projects in the high-tech and circular economy sectors. All consortia projects must have at least 1 eligible Japanese partner.

Participating countries include the United Kingdom, Canada, Austria, France, Singapore and Finland. This call for proposals is open to organizations who wish to form project consortia to perform collaborative projects focused on developing innovative products, processes or technology-based services.

This call for proposals is open to projects in the following sectors, excluding technologies associated with nuclear power and drug discovery:

• aerospace
• artificial intelligence
• biotechnology
• electronics
• energy and environment
• new materials
• medical devices
• mining and other industrial technologies
• robotics
• semiconductors
• quantum

Researchers are invited to apply for a new grant funding opportunity sponsored by Canadian Forces Health Services (CFHS) Director of Women and Diversity Health (D WDH) to conduct a systematic review exploring the possible effects of military occupational exposures on reproductive health outcomes in CAF women and diverse members. This systematic review is required to provide a rigorous and up to date overview of the evidence applicable to the CAF regarding occupational exposures and reproductive health outcomes in military women and diverse members. Researchers are encouraged to use a broad search strategy so that research conducted in militaries internationally, including comparable countries such as the UK and Australia, is included. Further, studies from grey literature should also be captured.

Researchers are invited to apply for a new grant funding opportunity sponsored by Canadian Forces Health Services (CFHS) Director of Women and Diversity Health (D WDH) to conduct a feasibility study. This feasibility study is required to provide D WDH with an understanding of the privacy, methodological, and resource implications of accessing health care utilization (HCU) and other routinely collected administrative data for research or surveillance with respect to health outcomes for women and diverse members in the Canadian Armed Forces (CAF).

This funding opportunity is seeking submissions to conduct an environmental scan of academic literature, public documents, emerging trends, best practices, and challenges in moral-ethical dilemma scenarios, including recommendations for a conjoint experiment.

Final report to include the following:

• Final research report that outlines new and emerging research, best practices and approaches for developing scenarios involving moral ethical dilemmas (including scenarios developed for VR environments).
• Identify and summarize academic literature and public documents regarding the types of virtual scenarios and key attributes of moral-ethical dilemmas relevant to military personnel.
• Example attributes for consideration include perspective, interaction with leadership, decision-making role, moral-ethical dilemmas, urgency, physical distance, naturalistic decision making, experience, demographic variables, and demographic factors like sex/gender and ethnicity.
• Provide recommendations on how to systematically evaluate the different features within each of the identified key attributes of scenarios involving moral-ethical dilemmas.
• Provide recommendations for gender-based analysis and considering factors from both end user and leadership perspectives.
• Provide recommendations for experimental design of a follow-up conjoint analysis from the end-user and leadership perspective based on the identified attributes and features from the environmental scan.
• Bibliography of documents used to produce the final report.

The funding opportunity seeks submissions to develop prototype predictive AI/ML models to assist trauma-induced blood transfusions. The models will use advanced machine learning algorithms and large-scale data to predict the need for massive hemorrhage protocol, the need for massive transfusion, and the transfusion of blood products (RBCs, plasma, and platelets) over time. The research can be conducted on a broader population, not just the Canadian Armed Forces (CAF) and Canadian Veteran populations.